## A: Agilent Technologies, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -1.7% below STRENGTH zone (4.0-10.0%); PEG 2.16 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($140.59)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Korea Investment CORP Lowers Holdings in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251130T110544 | Somewhat-Bullish | Relevance: 99%
- Korea Investment CORP reduced its stake in Agilent Technologies by 1.6%, selling 3,546 shares and holding 221,103 shares valued at $26.09 million. This occurred despite Agilent beating quarterly earnings and revenue estimates, reporting strong year-over-year revenue growth, and issuing positive FY2026 guidance, which led analysts to raise price targets. The company also increased its quarterly dividend, while CEO Padraig McDonnell sold 12,490 shares.

**2. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: BioSpace | 20251202T103950 | Bullish | Relevance: 99%
- Agilent Technologies announced new 21 CFR Part 11 compliance software for its xCELLigence Real-Time Cell Analysis (RTCA) eSight system. This upgrade extends the system's usability from drug discovery to GMP-regulated manufacturing and quality control settings by adding security features like user authentication, electronic signatures, and audit trails. The software addresses the growing need for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing, ensuring data integrity and streamlining regulatory submissions.

**3. Skandinaviska Enskilda Banken AB publ Trims Stake in Agilent Technologies, Inc. $A**
- Source: MarketBeat | 20251202T113308 | Somewhat-Bullish | Relevance: 98%
- Skandinaviska Enskilda Banken AB publ significantly trimmed its stake in Agilent Technologies by 36.8% in Q2 2025, selling over 32,000 shares and retaining a holding valued at $6.5 million. This occurred despite Agilent beating earnings estimates, providing positive FY2026 guidance, and increasing its quarterly dividend. The article also details other institutional investor activity, Agilent's stock performance, recent analyst ratings, and insider transactions, including a sale by CEO Padraig McDonnell.

**4. Agilent Announces 21 Cfr Part 11 Compliance Software For Xcelligence RTCA eSight**
- Source: TradingView | 20251201T142112 | Somewhat-Bullish | Relevance: 98%
- Agilent Technologies Inc. has announced the release of 21 CFR Part 11 Compliance Software for its Xcelligence RTCA eSight system. This software aims to help users involved in regulated research meet compliance standards. The announcement was made via Reuters.

**5. Agilent Announces 21 CFR Part 11 Compliance Software for xCELLigence RTCA eSight**
- Source: WebWire | 20251201T142636 | Bullish | Relevance: 98%
- Agilent Technologies (NYSE: A) has released new 21 CFR Part 11 compliance software for its xCELLigence RTCA eSight system, enabling its use in GMP-regulated manufacturing and quality control settings in addition to drug discovery labs. This upgrade provides enhanced security features, including audit trails, electronic signatures, and secure user authentication, addressing the growing demand for regulatory-ready digital lab tools in biopharma and cell therapy manufacturing. The software aims to support continuity from early-stage research to production, ensuring data integrity and audit-readiness across the drug development pipeline.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Goldman Sachs | $170 | $0 | 0% |
| 2025-12-02 | Morgan Stanley | $180 | $0 | 0% |
| 2025-11-25 | Citigroup | $185 | $165 | +12% |
| 2025-11-25 | UBS | $180 | $170 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Goldman Sachs | init | Buy |
| 2025-12-02 | Morgan Stanley | init | Overweight |
| 2025-11-25 | Citigroup | main | Buy |
| 2025-11-25 | UBS | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 10 ($1.37M) |
| Sells | 18 ($1.60M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.0% (+0.1%)
- Blackrock Inc.: 9.2% (+1.0%)
- Massachusetts Financ: 4.4% (-6.0%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.3% (+4.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 7 raises (avg +12%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.16 elevated, pricing in significant growth expectations. Forward P/E 22.7x stretched relative to 10% growth. Quality metrics strong (ROE 21%, margin 19%). Analyst sentiment positive (7 raises, avg +12%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $40.7B |
| Beta | 1.27 |
| 52W Range | $96.43 - $160.27 |
| Short Interest | 1.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.16 |
| Forward P/E | 22.7 |
| Current P/E | 25.0 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 7.0% to -1.7% (-8.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.7pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.67% (CS: 38) | Neutral |
| RSI_14 | 52.6 | Neutral |
| MACD Histogram | -0.15 | Bearish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 1.042x | Above |
| vs SMA200 | 1.203x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $148.81
- **Stop Loss:** $140.59 (5.5% risk)
- **Target:** $157.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 121
- **Position Value:** $18,006.01
- **Portfolio %:** 18.01%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-25 (Est: $1.37)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.58 | $1.59 | +0.4% |
| 2025Q3 | $1.37 | $1.37 | +0.2% |
| 2025Q2 | $1.26 | $1.31 | +3.6% |
| 2025Q1 | $1.27 | $1.31 | +3.0% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*